{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T18:59:00Z","timestamp":1793127540991,"version":"4.5.0"},"reference-count":67,"publisher":"American Diabetes Association","issue":"suppl_3","content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2004,12,1]]},"abstract":"<jats:p>Amylin is a peptide hormone that is cosecreted with insulin from the pancreatic \u03b2-cell and is thus deficient in diabetic people. It inhibits glucagon secretion, delays gastric emptying, and acts as a satiety agent. Amylin replacement could therefore possibly improve glycemic control in some people with diabetes. However, human amylin exhibits physicochemical properties predisposing the peptide hormone to aggregate and form amyloid fibers, which may play a part in \u03b2-cell destruction in type 2 diabetes. This obviously makes it unsuitable for pharmacological use. A stable analog, pramlintide, which has actions and pharmacokinetic and pharmacodynamic properties similar to the native peptide, has been developed. The efficacy and safety of pramlintide administration has been tested in a vast number of clinical trials. Aproximately 5,000 insulin-treated patients have received pramlintide and \u223c250 for \u22652 years. The aims of this review are to 1) briefly describe actions of amylin as demonstrated in animal and human models and 2) primarily review results from clinical trials with the amylin analog pramlintide.<\/jats:p>","DOI":"10.2337\/diabetes.53.suppl_3.s233","type":"journal-article","created":{"date-parts":[[2007,3,6]],"date-time":"2007-03-06T19:04:22Z","timestamp":1173207862000},"page":"S233-S238","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":196,"title":["Amylin Agonists: A Novel Approach in the Treatment of Diabetes"],"prefix":"10.2337","volume":"53","author":[{"given":"Ole","family":"Schmitz","sequence":"first","affiliation":[{"name":"From the Departments of Endocrinology and Diabetes, University Hospital of Aarhus; and the Department of Clinical Pharmacology, University of Aarhus, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgitte","family":"Brock","sequence":"additional","affiliation":[{"name":"From the Departments of Endocrinology and Diabetes, University Hospital of Aarhus; and the Department of Clinical Pharmacology, University of Aarhus, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorgen","family":"Rungby","sequence":"additional","affiliation":[{"name":"From the Departments of Endocrinology and Diabetes, University Hospital of Aarhus; and the Department of Clinical Pharmacology, University of Aarhus, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","reference":[{"key":"2022031209071550400_R1","doi-asserted-by":"crossref","unstructured":"Hartter E, Svoboda T, Ludvik B, Schuller M, Lell B, Kuenburg E, Brunnbauer M, Woloszczuk W, Prager R: Basal and stimulated plasma levels of pancreatic amylin indicate its co-secretion with insulin in humans. Diabetologia\u200834:52\u201354,1991","DOI":"10.1007\/BF00404025"},{"key":"2022031209071550400_R2","doi-asserted-by":"crossref","unstructured":"Nishi M, Sanke T, Seino S, Eddy RL, Fan YS, Byers MG, Shows TB, Bell GI, Steiner DF: Human islet amyloid polypeptide gene: complete nucleotide sequence, chromosomal localization, and evolutionary history. Mol Endocrinol\u20083:1775\u20131781,1989","DOI":"10.1210\/mend-3-11-1775"},{"key":"2022031209071550400_R3","doi-asserted-by":"crossref","unstructured":"McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J, Thompson N, Solari R, Lee MG, Foord SM: RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature\u2008393:333\u2013339,1998","DOI":"10.1038\/30666"},{"key":"2022031209071550400_R4","doi-asserted-by":"crossref","unstructured":"Muff R, Buhlmann N, Fischer JA, Born W: An amylin receptor is revealed following co-transfection of a calcitonin receptor with receptor activity modifying proteins-1 or -3. Endocrinology\u2008140:2924\u20132927,1999","DOI":"10.1210\/endo.140.6.6930"},{"key":"2022031209071550400_R5","doi-asserted-by":"crossref","unstructured":"American Diabetes Association: Standards of medical care in diabetes. Diabetes Care\u200827 (Suppl. 1):S15\u2013S35,2004","DOI":"10.2337\/diacare.27.2007.S15"},{"key":"2022031209071550400_R6","doi-asserted-by":"crossref","unstructured":"Vilsboll T, Holst JJ: Incretins, insulin secretion and type 2 diabetes mellitus. Diabetologia\u200847:357\u2013366,2004","DOI":"10.1007\/s00125-004-1342-6"},{"key":"2022031209071550400_R7","doi-asserted-by":"crossref","unstructured":"Cooper GJ, Willis AC, Clark A, Turner RC, Sim RB, Reid KB: Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci U S A\u200884:8628\u20138632,1987","DOI":"10.1073\/pnas.84.23.8628"},{"key":"2022031209071550400_R8","unstructured":"Westermark P, Wernstedt C, O\u2019Brien TD, Hayden DW, Johnson KH: Islet amyloid in type 2 human diabetes mellitus and adult diabetic cats contains a novel putative polypeptide hormone. Am J Pathol\u2008127:414\u2013417,1987"},{"key":"2022031209071550400_R9","unstructured":"Koda J, Fineman M, Kolterman O: 24-hour plasma amylin profiles are elevated in IGT subjects vs. normal controls (Abstract). Diabetes\u200844 (Suppl. 2):A238,1995"},{"key":"2022031209071550400_R10","doi-asserted-by":"crossref","unstructured":"Juhl CB, Porksen N, Sturis J, Hansen AP, Veldhuis JD, Pincus S, Fineman M, Schmitz O: High-frequency oscillations in circulating amylin concentrations in healthy humans. Am J Physiol Endocrinol Metab\u2008278:E484\u2013E490,2000","DOI":"10.1152\/ajpendo.2000.278.3.E484"},{"key":"2022031209071550400_R11","doi-asserted-by":"crossref","unstructured":"Nyholm B, Fineman MS, Koda JE, Schmitz O: Plasma amylin immunoreactivity and insulin resistance in insulin resistant relatives of patients with non-insulin-dependent diabetes mellitus. Horm Metab Res\u200830:206\u2013212,1998","DOI":"10.1055\/s-2007-978867"},{"key":"2022031209071550400_R12","doi-asserted-by":"crossref","unstructured":"Kautzky-Willer A, Thomaseth K, Pacini G, Clodi M, Ludvik B, Streli C, Waldhausl W, Prager R: Role of islet amyloid polypeptide secretion in insulin-resistant humans. Diabetologia\u200837:188\u2013194,1994","DOI":"10.1007\/s001250050092"},{"key":"2022031209071550400_R13","doi-asserted-by":"crossref","unstructured":"Hoppener JW, Ahren B, Lips CJ: Islet amyloid and type 2 diabetes mellitus. N Engl J Med\u2008343:411\u2013419,2000","DOI":"10.1056\/NEJM200008103430607"},{"key":"2022031209071550400_R14","doi-asserted-by":"crossref","unstructured":"Hull RL, Westermark GT, Westermark P, Kahn SE: Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes. J Clin Endocrinol Metab\u200889:3629\u20133643,2004","DOI":"10.1210\/jc.2004-0405"},{"key":"2022031209071550400_R15","unstructured":"Castillo MJ, Scheen AJ, Lefebvre PJ: Amylin\/islet amyloid polypeptide: biochemistry, physiology, pathophysiology. Diabete Metab\u200821:3\u201325,1995"},{"key":"2022031209071550400_R16","doi-asserted-by":"crossref","unstructured":"Wang ZL, Bennet WM, Ghatei MA, Byfield PG, Smith DM, Bloom SR: Influence of islet amyloid polypeptide and the 8-37 fragment of islet amyloid polypeptide on insulin release from perifused rat islets. Diabetes\u200842:330\u2013335,1993","DOI":"10.2337\/diabetes.42.2.330"},{"key":"2022031209071550400_R17","doi-asserted-by":"crossref","unstructured":"Martinez A, Kapas S, Miller MJ, Ward Y, Cuttitta F: Coexpression of receptors for adrenomedullin, calcitonin gene-related peptide, and amylin in pancreatic \u03b2-cells. Endocrinology\u2008141:406\u2013411,2000","DOI":"10.1210\/endo.141.1.7261"},{"key":"2022031209071550400_R18","doi-asserted-by":"crossref","unstructured":"Gedulin BR, Rink TJ, Young AA: Dose-response for glucagonostatic effect of amylin in rats. Metabolism\u200846:67\u201370,1997","DOI":"10.1016\/S0026-0495(97)90170-0"},{"key":"2022031209071550400_R19","unstructured":"Gedulin BR, Jodka C, Green D: Amylin inhibition of arginine-induced glucagon secretion: comparison with glucagon-like peptide-1 (7-36)-amide (GLP-1) (Abstract). Diabetologia\u200839 (Suppl.):A154,1996"},{"key":"2022031209071550400_R20","doi-asserted-by":"crossref","unstructured":"Silvestre RA, Rodriguez-Gallardo J, Jodka C, Parkes DG, Pittner RA, Young AA, Marco J: Selective amylin inhibition of the glucagon response to arginine is extrinsic to the pancreas. Am J Physiol Endocrinol Metab\u2008280:E443\u2013E449,2001","DOI":"10.1152\/ajpendo.2001.280.3.E443"},{"key":"2022031209071550400_R21","doi-asserted-by":"crossref","unstructured":"Macdonald IA: Amylin and the gastrointestinal tract. Diabet Med\u200814 (Suppl. 2):S24\u2013S28,1997","DOI":"10.1002\/(SICI)1096-9136(199706)14:2+<S24::AID-DIA399>3.0.CO;2-M"},{"key":"2022031209071550400_R22","doi-asserted-by":"crossref","unstructured":"Young AA, Gedulin BR, Rink TJ: Dose-responses for the slowing of gastric emptying in a rodent model by glucagon-like peptide (7-36) NH2, amylin, cholecystokinin, and other possible regulators of nutrient uptake. Metabolism\u200845:1\u20133,1996","DOI":"10.1016\/S0026-0495(96)90192-4"},{"key":"2022031209071550400_R23","doi-asserted-by":"crossref","unstructured":"Young AA, Gedulin B, Vine W, Percy A, Rink TJ: Gastric emptying is accelerated in diabetic BB rats and is slowed by subcutaneous injections of amylin. Diabetologia\u200838:642\u2013648,1995","DOI":"10.1007\/BF00401833"},{"key":"2022031209071550400_R24","unstructured":"Jodka C, Green D, Young A: Amylin modulation of gastric emptying in rats depends upon an intact vagus nerve (Abstract). Diabetes\u200845 (Suppl. 2):A235,1996"},{"key":"2022031209071550400_R25","doi-asserted-by":"crossref","unstructured":"Gedulin BR, Young AA: Hypoglycemia overrides amylin-mediated regulation of gastric emptying in rats. Diabetes\u200847:93\u201397,1998","DOI":"10.2337\/diabetes.47.1.93"},{"key":"2022031209071550400_R26","doi-asserted-by":"crossref","unstructured":"Morley JE, Flood JF, Farr SA, Perry HJ, III, Kaiser FE, Morley PM: Effects of amylin on appetite regulation and memory. Can J Physiol Pharmacol\u200873:1042\u20131046,1995","DOI":"10.1139\/y95-147"},{"key":"2022031209071550400_R27","doi-asserted-by":"crossref","unstructured":"Lutz TA, Del Prete E, Scharrer E: Reduction of food intake in rats by intraperitoneal injection of low doses of amylin. Physiol Behav\u200855:891\u2013895,1994","DOI":"10.1016\/0031-9384(94)90076-0"},{"key":"2022031209071550400_R28","doi-asserted-by":"crossref","unstructured":"Lutz TA, Del Prete E, Scharrer E: Subdiaphragmatic vagotomy does not influence the anorectic effect of amylin. Peptides\u200816:457\u2013462,1995","DOI":"10.1016\/0196-9781(94)00203-I"},{"key":"2022031209071550400_R29","unstructured":"Beaumont K, Kenney MA, Young AA, Rink TJ: High affinity amylin binding sites in rat brain. Mol Pharmacol\u200844:493\u2013497,1993"},{"key":"2022031209071550400_R30","doi-asserted-by":"crossref","unstructured":"Sexton PM, Paxinos G, Kenney MA, Wookey PJ, Beaumont K: In vitro autoradiographic localization of amylin binding sites in rat brain. Neuroscience\u200862:553\u2013567,1994","DOI":"10.1016\/0306-4522(94)90388-3"},{"key":"2022031209071550400_R31","doi-asserted-by":"crossref","unstructured":"Rogers RC, McTigue DM, Hermann GE: Vagal control of digestion: modulation by central neural and peripheral endocrine factors. Neurosci Biobehav Rev\u200820:57\u201366,1996","DOI":"10.1016\/0149-7634(95)00040-L"},{"key":"2022031209071550400_R32","doi-asserted-by":"crossref","unstructured":"Bretherton-Watt D, Gilbey SG, Ghatei MA, Beacham J, Bloom SR: Failure to establish islet amyloid polypeptide (amylin) as a circulating beta cell inhibiting hormone in man. Diabetologia\u200833:115\u2013117,1990","DOI":"10.1007\/BF00401050"},{"key":"2022031209071550400_R33","doi-asserted-by":"crossref","unstructured":"Bretherton-Watt D, Gilbey SG, Ghatei MA, Beacham J, Macrae AD, Bloom SR: Very high concentrations of islet amyloid polypeptide are necessary to alter the insulin response to intravenous glucose in man. J Clin Endocrinol Metab\u200874:1032\u20131035,1992","DOI":"10.1210\/jcem.74.5.1569151"},{"key":"2022031209071550400_R34","doi-asserted-by":"crossref","unstructured":"Wilding JP, Khandan-Nia N, Bennet WM, Gilbey SG, Beacham J, Ghatei MA, Bloom SR: Lack of acute effect of amylin (islet associated polypeptide) on insulin sensitivity during hyperinsulinaemic euglycaemic clamp in humans. Diabetologia\u200837:166\u2013169,1994","DOI":"10.1007\/s001250050088"},{"key":"2022031209071550400_R35","doi-asserted-by":"crossref","unstructured":"Zierath JR, Galuska D, Engstrom A, Johnson KH, Betsholtz C, Westermark P, Wallberg-Henriksson H: Human islet amyloid polypeptide at pharmacological levels inhibits insulin and phorbol ester-stimulated glucose transport in in vitro incubated human muscle strips. Diabetologia\u200835:26\u201331,1992","DOI":"10.1007\/BF00400848"},{"key":"2022031209071550400_R36","doi-asserted-by":"crossref","unstructured":"Goldsbury CS, Cooper GJ, Goldie KN, Muller SA, Saafi EL, Gruijters WT, Misur MP, Engel A, Aebi U, Kistler J: Polymorphic fibrillar assembly of human amylin. J Struct Biol\u2008119:17\u201327,1997","DOI":"10.1006\/jsbi.1997.3858"},{"key":"2022031209071550400_R37","doi-asserted-by":"crossref","unstructured":"Westermark P, Engstrom U, Johnson KH, Westermark GT, Betsholtz C: Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. Proc Natl Acad Sci U S A\u200887:5036\u20135040,1990","DOI":"10.1073\/pnas.87.13.5036"},{"key":"2022031209071550400_R38","doi-asserted-by":"crossref","unstructured":"Jaikaran ET, Higham CE, Serpell LC, Zurdo J, Gross M, Clark A, Fraser PE: Identification of a novel human islet amyloid polypeptide beta-sheet domain and factors influencing fibrillogenesis. J Mol Biol\u2008308:515\u2013525,2001","DOI":"10.1006\/jmbi.2001.4593"},{"key":"2022031209071550400_R39","doi-asserted-by":"crossref","unstructured":"Colburn WA, Gottlieb AB, Koda J, Kolterman OG: Pharmacokinetics and pharmacodynamics of AC137 (25,28,29 tripro-amylin, human) after intravenous bolus and infusion doses in patients with insulin-dependent diabetes. J Clin Pharmacol\u200836:13\u201324,1996","DOI":"10.1002\/j.1552-4604.1996.tb04147.x"},{"key":"2022031209071550400_R40","doi-asserted-by":"crossref","unstructured":"Young AA, Vine W, Gedulin B: Preclinical pharmacology of pramlintide in the rat: comparison with human and rat amylin. Drug Dev Res\u200837:231\u2013248,1996","DOI":"10.1002\/(SICI)1098-2299(199604)37:4<231::AID-DDR5>3.0.CO;2-M"},{"key":"2022031209071550400_R41","doi-asserted-by":"crossref","unstructured":"Sakurai H, Dobbs RE, Unger RH: The role of glucagon in the pathogenesis of the endogenous hyperglycemia of diabetes mellitus. Metabolism\u200824:1287\u20131297,1975","DOI":"10.1016\/0026-0495(75)90067-0"},{"key":"2022031209071550400_R42","doi-asserted-by":"crossref","unstructured":"American Diabetes Association: Postprandial blood glucose. Diabetes Care\u200824 (Suppl. 1):775\u2013778,2001","DOI":"10.2337\/diacare.24.4.775"},{"key":"2022031209071550400_R43","doi-asserted-by":"crossref","unstructured":"Kolterman OG, Gottlieb A, Moyses C, Colburn W: Reduction of postprandial hyperglycemia in subjects with IDDM by intravenous infusion of AC137, a human amylin analogue. Diabetes Care\u200818:1179\u20131182,1995","DOI":"10.2337\/diacare.18.8.1179"},{"key":"2022031209071550400_R44","doi-asserted-by":"crossref","unstructured":"Kong MF, King P, Macdonald IA, Stubbs TA, Perkins AC, Blackshaw PE, Moyses C, Tattersall RB: Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM. Diabetologia\u200840:82\u201388,1997","DOI":"10.1007\/s001250050646"},{"key":"2022031209071550400_R45","doi-asserted-by":"crossref","unstructured":"Thompson RG, Gottlieb A, Organ K, Koda J, Kisicki J, Kolterman OG: Pramlintide: a human amylin analogue reduced postprandial plasma glucose, insulin, and C-peptide concentrations in patients with type 2 diabetes. Diabet Med\u200814:547\u2013555,1997","DOI":"10.1002\/(SICI)1096-9136(199707)14:7<547::AID-DIA390>3.0.CO;2-U"},{"key":"2022031209071550400_R46","doi-asserted-by":"crossref","unstructured":"Nyholm B, Moller N, Gravholt CH, Orskov L, Mengel A, Bryan G, Moyses C, Alberti KG, Schmitz O: Acute effects of the human amylin analog AC137 on basal and insulin-stimulated euglycemic and hypoglycemic fuel metabolism in patients with insulin-dependent diabetes mellitus. J Clin Endocrinol Metab\u200881:1083\u20131089,1996","DOI":"10.1210\/jcem.81.3.8772580"},{"key":"2022031209071550400_R47","doi-asserted-by":"crossref","unstructured":"Mather KJ, Paradisi G, Leaming R, Hook G, Steinberg HO, Fineberg N, Hanley R, Baron AD: Role of amylin in insulin secretion and action in humans: antagonist studies across the spectrum of insulin sensitivity. Diabetes Metab Res Rev\u200818:118\u2013126,2002","DOI":"10.1002\/dmrr.263"},{"key":"2022031209071550400_R48","doi-asserted-by":"crossref","unstructured":"Kolterman OG, Schwartz S, Corder C, Levy B, Klaff L, Peterson J, Gottlieb A: Effect of 14 days\u2019 subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM. Diabetologia\u200839:492\u2013499,1996","DOI":"10.1007\/BF00400683"},{"key":"2022031209071550400_R49","doi-asserted-by":"crossref","unstructured":"Thompson RG, Peterson J, Gottlieb A, Mullane J: Effects of pramlintide, an analog of human amylin, on plasma glucose profiles in patients with IDDM: results of a multicenter trial. Diabetes\u200846:632\u2013636,1997","DOI":"10.2337\/diabetes.46.4.632"},{"key":"2022031209071550400_R50","doi-asserted-by":"crossref","unstructured":"Thompson RG, Pearson L, Kolterman OG: Effects of 4 weeks\u2019 administration of pramlintide, a human amylin analogue, on glycaemia control in patients with IDDM: effects on plasma glucose profiles and serum fructosamine concentrations. Diabetologia\u200840:1278\u20131285,1997","DOI":"10.1007\/s001250050821"},{"key":"2022031209071550400_R51","doi-asserted-by":"crossref","unstructured":"Nyholm B, Orskov L, Hove KY, Gravholt CH, Moller N, Alberti KG, Moyses C, Kolterman O, Schmitz O: The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus. Metabolism\u200848:935\u2013941,1999","DOI":"10.1016\/S0026-0495(99)90232-9"},{"key":"2022031209071550400_R52","doi-asserted-by":"crossref","unstructured":"Young AA, Crocker LB, Wolfe-Lopez D, Cooper GJ: Daily amylin replacement reverses hepatic glycogen depletion in insulin-treated streptozotocin diabetic rats. FEBS Lett\u2008287:203\u2013205,1991","DOI":"10.1016\/0014-5793(91)80051-4"},{"key":"2022031209071550400_R53","doi-asserted-by":"crossref","unstructured":"Orskov L, Nyholm B, Yde HK, Gravholt CH, Moller N, Schmitz O: Effects of the amylin analogue pramlintide on hepatic glucagon responses and intermediary metabolism in type 1 diabetic subjects. Diabet Med\u200816:867\u2013874,1999","DOI":"10.1046\/j.1464-5491.1999.00162.x"},{"key":"2022031209071550400_R54","doi-asserted-by":"crossref","unstructured":"Levetan C, Want LL, Weyer C, Strobel SA, Crean J, Wang Y, Maggs DG, Kolterman OG, Chandran M, Mudaliar SR, Henry RR: Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps. Diabetes Care\u200826:1\u20138,2003","DOI":"10.2337\/diacare.26.1.1"},{"key":"2022031209071550400_R55","doi-asserted-by":"crossref","unstructured":"Weyer C, Gottlieb A, Kim DD, Lutz K, Schwartz S, Gutierrez M, Wang Y, Ruggles JA, Kolterman OG, Maggs DG: Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study. Diabetes Care\u200826:3074\u20133079,2003","DOI":"10.2337\/diacare.26.11.3074"},{"key":"2022031209071550400_R56","doi-asserted-by":"crossref","unstructured":"Fineman MS, Koda JE, Shen LZ, Strobel SA, Maggs DG, Weyer C, Kolterman OG: The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes. Metabolism\u200851:636\u2013641,2002","DOI":"10.1053\/meta.2002.32022"},{"key":"2022031209071550400_R57","doi-asserted-by":"crossref","unstructured":"Fineman M, Weyer C, Maggs DG, Strobel S, Kolterman OG: The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus. Horm Metab Res\u200834:504\u2013508,2002","DOI":"10.1055\/s-2002-34790"},{"key":"2022031209071550400_R58","doi-asserted-by":"crossref","unstructured":"Ludvik B, Thomaseth K, Nolan JJ, Clodi M, Prager R, Pacini G: Inverse relation between amylin and glucagon secretion in healthy and diabetic human subjects. Eur J Clin Invest\u200833:316\u2013322,2003","DOI":"10.1046\/j.1365-2362.2003.01142.x"},{"key":"2022031209071550400_R59","doi-asserted-by":"crossref","unstructured":"Dinneen S, Alzaid A, Turk D, Rizza R: Failure of glucagon suppression contributes to postprandial hyperglycaemia in IDDM. Diabetologia\u200838:337\u2013343,1995","DOI":"10.1007\/BF00400639"},{"key":"2022031209071550400_R60","doi-asserted-by":"crossref","unstructured":"Dinneen S, Gerich J, Rizza R: Carbohydrate metabolism in non-insulin-dependent diabetes mellitus. N Engl J Med\u2008327:707\u2013713,1992","DOI":"10.1056\/NEJM199209033271007"},{"key":"2022031209071550400_R61","doi-asserted-by":"crossref","unstructured":"Baron AD, Schaeffer L, Shragg P, Kolterman OG: Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics. Diabetes\u200836:274\u2013283,1987","DOI":"10.2337\/diabetes.36.3.274"},{"key":"2022031209071550400_R62","doi-asserted-by":"crossref","unstructured":"Ahren B, Adner N, Svartberg J, Petrella E, Holst JJ, Gutniak MK: Anti-diabetogenic effect of the human amylin analogue, pramlintide, in type 1 diabetes is not mediated by GLP-1. Diabet Med\u200819:790\u2013792,2002","DOI":"10.1046\/j.1464-5491.2002.00657_1.x"},{"key":"2022031209071550400_R63","doi-asserted-by":"crossref","unstructured":"Whitehouse F, Kruger DF, Fineman M, Shen L, Ruggles JA, Maggs DG, Weyer C, Kolterman OG: A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care\u200825:724\u2013730,2002","DOI":"10.2337\/diacare.25.4.724"},{"key":"2022031209071550400_R64","doi-asserted-by":"crossref","unstructured":"Hollander PA, Levy P, Fineman MS, Maggs DG, Shen LZ, Strobel SA, Weyer C, Kolterman OG: Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care\u200826:784\u2013790,2003","DOI":"10.2337\/diacare.26.3.784"},{"key":"2022031209071550400_R65","doi-asserted-by":"crossref","unstructured":"Hollander P, Ratner R, Fineman M, Strobel S, Shen L, Maggs D, Kolterman O, Weyer C: Addition of pramlintide to insulin therapy lowers HbA1c in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets. Diabetes Obes Metab\u20085:408\u2013414,2003","DOI":"10.1046\/j.1463-1326.2003.00295.x"},{"key":"2022031209071550400_R66","doi-asserted-by":"crossref","unstructured":"Hollander P, Maggs DG, Ruggles JA, Fineman M, Shen L, Kolterman OG, Weyer C: Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients. Obes Res\u200812:661\u2013668,2004","DOI":"10.1038\/oby.2004.76"},{"key":"2022031209071550400_R67","doi-asserted-by":"crossref","unstructured":"Moller DE: New drug targets for type 2 diabetes and the metabolic syndrome. Nature\u2008414:821\u2013827,2001","DOI":"10.1038\/414821a"}],"container-title":["Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.org\/diabetes\/diabetes\/article-pdf\/53\/suppl_3\/S233\/379792\/zdb1120400s233.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article-pdf\/53\/suppl_3\/S233\/379792\/zdb1120400s233.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T16:23:33Z","timestamp":1667406213000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article\/53\/suppl_3\/S233\/13874\/Amylin-Agonists-A-Novel-Approach-in-the-Treatment"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,12,1]]},"references-count":67,"journal-issue":{"issue":"suppl_3","published-print":{"date-parts":[[2004,12,1]]}},"URL":"https:\/\/doi.org\/10.2337\/diabetes.53.suppl_3.s233","relation":{},"ISSN":["0012-1797","1939-327X"],"issn-type":[{"value":"0012-1797","type":"print"},{"value":"1939-327X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,12,1]]}}}